Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Non Operating Investment Income (2020 - 2025)

ImmunityBio (IBRX) has disclosed Non Operating Investment Income for 6 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Investment Income rose 93.6% to $2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.4 million, a 19.69% decrease, with the full-year FY2025 number at $6.4 million, down 19.69% from a year prior.
  • Non Operating Investment Income was $2.3 million for Q4 2025 at ImmunityBio, up from $2.1 million in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $8.9 million in Q1 2021 to a low of -$6.9 million in Q4 2021.
  • A 5-year average of $416050.0 and a median of $872000.0 in 2022 define the central range for Non Operating Investment Income.
  • Peak YoY movement for Non Operating Investment Income: plummeted 4087.25% in 2021, then skyrocketed 5037.14% in 2024.
  • ImmunityBio's Non Operating Investment Income stood at -$6.9 million in 2021, then soared by 44.95% to -$3.8 million in 2022, then skyrocketed by 112.69% to $484000.0 in 2023, then surged by 145.25% to $1.2 million in 2024, then skyrocketed by 93.6% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Non Operating Investment Income are $2.3 million (Q4 2025), $2.1 million (Q3 2025), and $1.2 million (Q2 2025).